CureFAKtor Pharmaceuticals LLC
This article was originally published in Start Up
CureFAKtor Pharmaceuticals is one of a growing number of companies aimg to create effective cancer drugs by targeting an enzyme known as FAK, short for focal adhesion kinase, which like all kinases provides a binding site for ATP. Most commercial research on FAK has been oriented to blocking ATP as a way of slowing or stopping the growth of cancer cells, but CureFAKtor believes that the complexity of FAK's molecular structure offers the opportunity to block various sites, not just ATP, with an array of small molecules, and thus treat cancer by targeting multiple sites of interaction relevant to individual patient tumors.
You may also be interested in...
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.